DTB struggles to assess perampanel’s place in therapy
Assessing the place of perampanel in the treatment of epilepsy is hampered by a lack of comparative controlled trials and published health economic analyses, according to the latest .
However, the DTB concludes that, on current evidence, “perampanel is an extra drug to add to the list of adjunctive treatments to be considered by a tertiary epilepsy specialist”.
The bulletin highlights that the number needed to treat to achieve at least a 50 per cent reduction in seizure frequency is five and that complete freedom from seizures is achieved in 5 per cent of patients with the highest dose of perampanel. The cost of perampanel is more than that of many other adjunctive drugs but comparable to the newer antiepileptics, it says.
Citation: Electronicjuice DOI: 10.1211/PJ.2013.11116821
Recommended from Pharmaceutical Press
Four practice tests, each with 80 practice-oriented MCQs. Assess your knowledge of clinical issues, evaluative and analytical skills.£25.00
Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.£38.00
A study aid with 800 MCQs. Assess your knowledge, analytical skills, and ability to apply this knowledge base in clinical practice.£25.00
A clear and concise basic pharmacokinetics textbook. Shows how to apply the principles to achieve successful drug therapy.£54.00
Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.£43.00